In 1972, news broke that the U.S. Public Health Service had studied untreated syphilis in hundreds of Black men in Tuskegee, Alabama, for 40 years, even after penicillin became available. The revelation shocked the public and changed research forever. Bioethics grew out of that reckoning. It examines the moral questions raised by biology, medicine, and biotechnology.

The field covers a wide range of issues. Informed consent asks whether patients and research subjects understand what they are agreeing to. Privacy asks who owns genetic data and who can access it. Equity asks who benefits from new therapies and who is left out. Gene editing asks whether we should alter human embryos. End-of-life care asks how we define death and who decides when to stop treatment.

Bioethics is not a single answer. It is a process of reasoning. Four principles guide much of the field: autonomy, beneficence, non-maleficence, and justice. Autonomy respects the patient's choices. Beneficence promotes well-being. Non-maleficence avoids harm. Justice distributes benefits and burdens fairly. These principles often conflict, and resolving the conflict requires judgment.

Bioethics committees review research protocols, advise hospitals, and shape policy. The field is not abstract. It decides whether a trial can proceed, whether a drug is approved, and whether a patient can refuse treatment. The stakes are personal.